Free Newsletter
Forbes digs into 'Pfizer's Nigerian nightmare'
As Pfizer negotiates a settlement with the Nigerian government in the long-running dispute over the Trovan drug trial there--and a U.S. federal appeals court considers whether Nigerian plaintiffs can sue the drugmaker here--Forbes delves into the background of the case, looking at documents and interviewing Pfizer officials, victims' families, and the FDA. An "unsettling look at the pitfalls of doing hurried drug trials in Third World countries," the story could be a cautionary tale for drugmakers conducting an increasing amount of research in the developing world. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment